GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » EPS (Basic)

RGTLF (Argent Biopharma) EPS (Basic) : $-0.36 (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Argent Biopharma EPS (Basic)?

Argent Biopharma's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was $-0.15. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.36.

Argent Biopharma's EPS (Diluted) for the six months ended in Jun. 2024 was $-0.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.36.

Argent Biopharma's EPS without NRI for the six months ended in Jun. 2024 was $-0.15. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -0.36.

During the past 3 years, the average EPS without NRI Growth Rate was 56.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -12.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Argent Biopharma's highest 3-Year average EPS without NRI Growth Rate was 75.10% per year. The lowest was -233.40% per year. And the median was 15.40% per year.

Argent Biopharma EPS (Basic) Historical Data

The historical data trend for Argent Biopharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma EPS (Basic) Chart

Argent Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.66 -6.35 -5.55 -4.77 -0.31

Argent Biopharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.23 -2.83 -1.95 -0.21 -0.15

Argent Biopharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Argent Biopharma's Basic EPS for the fiscal year that ended in Jun. 2024 is calculated as

Basic EPS (A: Jun. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.641-0)/37.012
=-0.31

Argent Biopharma's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.942-0)/50.930
=-0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma  (OTCPK:RGTLF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Argent Biopharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » EPS (Basic)
Comparable Companies
ASX:PER ASX:EXL ASX:EOF ASX:AGH ASX:BP8 ASX:IVX ASX:CAN ASX:ECS ASX:NXS ASX:LGP ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
RGT:UK H5O0:Germany RGT:Australia
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Website
https://www.argentbiopharma.com
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.